Insilico Medicine has announced positive preliminary results from its Phase IIa clinical trial of ISM001-055, a small ...

The Hong Kong headquartered company says its idiopathic pulmonary fibrosis drug performed well in a phase 2a trial and met ...

A biotech that uses artificial intelligence to assist its drug discovery efforts has relocated its headquarters from New York ...

SAN FRANCISCO — While generative AI (AI) is being hailed as a game-changer as it sweeps the globe, the concept of “in silico medicine,” or computational medicine, is not exactly a new one.

Insilico Medicine(“Insilico”), a clinical-stage generative artificial intelligence (AI)-driven biotechnology company, today announced that the company has achieved a groundbreaking collaboration with ...

Insilico Medicine, a clinical-stage generative AI-driven drug discovery company, announced positive preliminary results ...

Hong Kong’s Insilico Medicine has found a way to use AI and deep learning to design, synthesise and validate a novel drug candidate in 46 days – 15 times faster than the best pharma companies.

Insilico Medicine("Insilico"), a clinical-stage generative artificial intelligence (AI)-driven biotechnology company, today announced that the company has achieved a groundbreaking collaboration ...

Insilico Medicine(“Insilico”), a clinical-stage generative artificial intelligence (AI)-driven biotechnology company, today announced the nomination of ISM2196, an AI-driven, potential best-in-class ...

Insilico Medicine, a clinical stage biotech company powered by generative artificial intelligence (AI), is connecting biology, chemistry and clinical trials analysis using next-generation AI systems.

Insilico Medicine has announced positive preliminary results from its Phase IIa clinical trial of ISM001-055, a small molecule drug designed using generative AI, to treat idiopathic pulmonary ...